Blood nitrates content in patients with systemic lupus erythematosus and antiphospholipid syndrome
- Authors: Reshetnyak DV1, Kuznetsova TV2, Kobylyansky AG2, Klyukvina NG1, Reshetnyak TM3, Nasonov EL3
-
Affiliations:
- ММА им. И. М. Сеченова
- Российский кардиологический научно-производственный комплекс Минздрава РФ
- ГУ институт ревматологии РАМН
- Issue: Vol 79, No 5 (2004)
- Pages: 19-22
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/29795
- ID: 29795
Cite item
Full Text
Abstract
Material and methods. Blood serum concentration of N03 was measured by high-performance liquid chromatography in a total of 41 patients with SLE (n = 17), PAPS (n = 14) and secondary APS (n - 9). Sera from 10 healthy subjects (donors) served as control. N03 concentration > 40 mcmol/l was stated high. SLE activity was assessed by V. A. Nasonova 's scale and SLEDAI index (SLEDAI > 9 indicated SLE exacerbation). Patients with PAPS were divided into two groups depending on clinical symptoms: 7 patients with significant thrombosis or history of more than two thrombotic complications (group 1); 7patients with the history of two or less thromboses (group 2). Results. The mean serum nitrate concentration in the SLE group was 43.59 mcmol/l (range 17.06113.22). The nitrate level of the sAPS + SLE group was 49.81 ± 27.54 and did not significantly differ from APS (33.67 ± 14.70). By univariate standard analyses, serum nitrate concentration was significantly higher in patients with high disease activity (57.31 ± 25.12 vs. 25.62 ± 6.96, Mann-Whitney test, p < 0.01). The Spearman correlation coefficient of nitrate level with SLEDAI was 0.8 (p < 0.001). Conclusion. A nitrate level is increased in patients with active SLE and in APS patients with severe thrombotic complication.
About the authors
D V Reshetnyak
ММА им. И. М. СеченоваММА им. И. М. Сеченова
T V Kuznetsova
Российский кардиологический научно-производственный комплекс Минздрава РФМосква; Российский кардиологический научно-производственный комплекс Минздрава РФ
A G Kobylyansky
Российский кардиологический научно-производственный комплекс Минздрава РФМосква; Российский кардиологический научно-производственный комплекс Минздрава РФ
N G Klyukvina
ММА им. И. М. СеченоваММА им. И. М. Сеченова
T M Reshetnyak
ГУ институт ревматологии РАМНГУ институт ревматологии РАМН
E L Nasonov
ГУ институт ревматологии РАМНГУ институт ревматологии РАМН
References
- Clancy R. M., Amin A. R., Abramson S. B. The role of nitric oxide in inflammation and immunity. Arthr. and Rheum. 1998; 41 (7): 1141-1151.
- Farrell A. J., Blake D. R. Nitric oxide. Ann. Rheum. Dis. 1996; 55: 7-20.
- Tan E. M., Cohen A. S., Fries J. F. The 1982 revised criteria for the classification of systemic lupus erythematosus (SLE). Arthr. and Rheum. 1982; 25: 1271-1277.
- Bombardier C., Gladman D. D., Urowits M. B. et al. The development and validation of the SLE disease activity index (SLE-DAI). Arthr. and Rheum. 1992; 35: 630-640.
- Wilson W. A., Gharavi A. E., Koike T. et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthr. and Rheum. 1999; 42: 1309-1311.
- Кобылянский А. Г., Кузнецова Т. В., Соболева Г. Н. и лр. Определение оксида азота в сыворотке и плазме крови человека. Метод высокоэффективной жидкостной хроматографии. Биомед. химия 2003; 6.
- Александрова Е. И., Насонов Е. Л., Ковалев В. Ю. Количественный иммуноферментный метод определения антител к кардиолипину в сыворотке крови. Клин, ревматол. 1995; 4: 35-39.
- Но С. Y., Wong С. К., Li E. К. et al. Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2003; 42 (1): 117-122.
- Wanchu A., Khullar M., Deodhar S. D. et al. Nitric oxide synthesis is increased in patients with systemic lupus erythematosus. Rheumatol. Int. 1998; 18 (2): 41-43.
- Belmont H. M., Levartovsky D., Goel A. et al. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthr. and Rheum. 1997; 40 (10): 1810-1816.
- Wigand R., Meyer J., Busse R., Becker M. Increased serum NG-hydroxy-L-arginine in patients with rheumatoid arthritis and systemic lupus erythematosus as an index of an increased nitric oxide synthase activity. Ann. Rheum. Dis. 1997; 56 (5): 330-332.
- Wong С. К, Но С. Y., Li E. К. et al. Elevated production of interleukin-18 is associated with renal disease in patients with systemic lupus erythematosus. Clin. Exp. Immunol. 2002; 130 (2): 345-351.
- Wang J. S., Tseng H. H., Shih D. F. et al. Expression of inducible nitric oxide synthase and apoptosis in human lupus nephritis. Nephron 1997; 77 (4): 404-411.
- Reilty С. M., Family L. W., Viti D. et al. Modulation of renal disease in MRL/lpr mice by pharmacologic inhibition of inducible nitric oxide synthase. Kidney Int. 2002; 61 (3): 839- 846.
- Jonsson С. A., Carbten H. Mycophenolic acid inhibits inosine 5'-monophosphate dehydrogenase and suppresses production of pro-inflammatory cytokines, nitric oxide, and LDH in macrophages. Cell. Immunol. 2002; 216 (1-2): 93-101.
- Yu С. С., Yang С. W., Wu M. S. et al. Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice. J. Lab. Clin. Med. 2001; 138 (1): 69-77.
- Lui S. L., Tsang A., Wong D. et al. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice. Lupus 2002; 11 (7): 411-418.
- Huang F. P., Feng G. J., Lindop G. et al. The role of interleukin 12 and nitric oxide in the development of spontaneous autoimmune disease in MRL inverted question markMP-lpr inverted question marklpr mice. J. Exp. Med. 1996; 183 (4): 1447-1459.
- At Suwaidi J., Hamasaki S., Higano S. T. et al. Long-term follow-up of patients with mild coronary artery disease and endothelial disfunction. Circulation 2000; 101: 948-954.
- Lima D. S. N., Sato E. I., Lima V. С. et al. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J. Rheumatol. 2002; 29: 292-297.
![](/img/style/loading.gif)